Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Top Cited Papers
- 20 June 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (10), 1474-1482
- https://doi.org/10.1016/j.jtho.2018.05.041
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialThe Lancet Oncology, 2017
- ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialThe Lancet Oncology, 2016
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerJournal of Thoracic Oncology, 2015
- The distribution of BRAF gene fusions in solid tumors and response to targeted therapyInternational Journal of Cancer, 2015
- Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancersLaboratory Investigation, 2014
- Molecular Pathways: ROS1 Fusion Proteins in CancerClinical Cancer Research, 2013
- Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase FusionsClinical Cancer Research, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor TreatmentClinical Cancer Research, 2010